ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—A propensity-score matching comparative study
Provisionally accepted
- 1Shandong Tumor Hospital, Jinan, China
- 2Tianjin Baodi Hospital, Tianjin, China
- 3Central Hospital Affiliated to Shandong First Medical University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Purpose: The present study aimed to comparatively examine transarterial chemoembolization (TACE) plus hepatic arterial infusion chemotherapy (HAIC) in combination with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) versus HAIC alone in combination with TKIs and ICIs for efficacy and safety in individuals with high tumor burden (major portal vein tumor thrombosis [PVTT] Vp3-4 or/and tumors larger than 10 cm) hepatocellular carcinoma (HCC). Methods: Totally 363 inoperable HCC cases with high tumor burden administered TACE-HAIC plus TKI and ICI (TACE-HAIC combination group, n=119) or HAIC plus TKI and ICI (HAIC combination group, n=244) were recruited between October 2020 and January 2024, and propensity score matching (PSM) was utilized for matching patients. Overall survival (OS), progression-free survival (PFS), objective response (ORR), disease control (DCR) rates, and safety signals were assessed. Results: Following PSM (1:2), 87 cases in the TACE-HAIC combination group were matched to 143 cases in the HAIC combination group. Median OS (26.8 vs. 19.1 months, p=0.233) and PFS (11.17 vs. 9.01 months, p=0.133) were similar in the TACE-HAIC and HAIC combination groups. ORRs were 58.0% and 64.4% in the HAIC and TACE-HAIC combination groups, respectively (p=0.341). DCR were 90.9% and 94.3% for these groups, respectively (p=0.360). Both univariate and multivariate analyses revealed no differences between the two groups pre-and post-matching. The commonest adverse events (AEs) included thrombocytopenia, hypertension, and increased AST (aspartate aminotransferase) and ALT (alanine aminotransferase) of any grade pre-and post-PSM. Conclusions: For HCC patients with high tumor burden, HAIC demonstrates comparable efficacy to TACE-HAIC both in combination with TKIs and ICIs. Therefore, HAIC should be the preferred local therapeutic strategy over TACE-HAIC in HCC patients with high tumor burden.
Keywords: Hepatocellular Carcinoma, transarterial chemoembolization (TACE), Hepatic arterial infusion chemotherapy (HAIC), combination therapy, high tumor burden
Received: 12 Jul 2025; Accepted: 03 Nov 2025.
Copyright: © 2025 Wu, dong, Li, Shao, Wang, Wu and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Huiyong Wu, jinanwhy@163.com
Xu Chang, cx18769785023@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.